Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

NCT05526924 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Head and Neck Carcinoma
Head and Neck Cancer Stage IV
Head and Neck Cancers - Throat

Interventions

RADIATION: Chemoradiation
DRUG: Pamiparib
DRUG: Hydroxyurea
DRUG: Fluorouracil (5FU)
DRUG: Tislelizumab

Sponsor

University of Chicago